Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor

Journal of Infectious Diseases

Volumn 178, Issue 3, 1998, Pages 815-819

  Draper, Deborah ^a   Donohoe, William ^b   Mortimer, Leo ^b   Phillip Heine, R ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE PROTEINASE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RISK FACTOR; SALIVA; SEXUALLY TRANSMITTED DISEASE; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; VAGINA DISCHARGE; VIRUS TRANSMISSION;

EID: 0031706501     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515366     Document Type: Article

References (22)

1. Rein M, Muller M. Trichomonas vaginalis. In: Holmes KK, Mardh PA, Sparling PF, Weisner PJ, eds. Sexually transmitted diseases. New York: McGraw Hill, 1984:525-36.
2. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61-77.
3. Franken C, Meijer CJLM, Dijkman JH. Tissue distribution of antileukoprotease and lysozyme in humans. J Histochem Cytochem 1989;37: 493-8.
4. Vogelmeier C, Hubbard RC, Fells GA, et al. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest 1991; 87:482-8.
5. Jin F, Nathan C, Radzioch D, Ding A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 1997;88:417-26.
6. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH. Antibacterial activity of antileukoprotease. Infect Immun 1996; 64:4520-4.
7. McNeely TB, Dealy M, Dripps D, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995;96:456-64.
8. Archibald DN, Cole GA. In vitro inhibition of HIV-1 infectivity by human saliva. AIDS Res Hum Retroviruses 1990;6:1425-32.
9. Shine N, Konopka K, Duzgunes N. The anti-HIV-1 activity associated with saliva. A concise review. J Dental Res 1997; 76:634-40.
10. Kramps JA, Franken C, Dijkman JH. ELISA for quantitative measurement of low-molecular-weight bronchial protease inhibitor in human sputum. Am Rev Respir Dis 1984; 129:959-63.
11. Zhang Y, DeWitt DL, McNeely TB, Whal SM, Wahl LM. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2 and matrix metalloproteases. J Clin Invest 1997;99:894-900.
12. Towbin HT, Staehlin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4.
13. Laemmeli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-5.
14. Eisenberg S, Hale KK, Heimdal P, Thompson RC. Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. J Biol Chem 1990;265:7976-81.
15. Turpin JA, Schaffer CA, Bu M, et al. Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor. Antiviral Res 1996; 29:269-77.
16. Bélec L, Tevi-Benissan C, Malta M, Ali SM. Secretory leukocyte protease inhibitor (SLPI) in cervico-vaginal secretions from HIV-negative and HIV-positive women [abstract Tu.C.2685]. In: Program and abstracts: XI International Conference on AIDS (Vancouver, Canada). Vancouver: XI International Conference on AIDS Society, 1996.
17. Abe T, Kobayashi N, Yoshimuraa K, et al. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Invest 1991; 87: 2207-15.
18. Alderete JF, Newton E, Dennis C, Neal KA. Antibody in sera of patients infected with Trichomonas vaginalis is to trichomonal proteinases. Genitourin Med 1991;67:331-4.
19. Alderete JF, Newton E, Dennis C, Neale KA. The vagina of women infected with Trichomonas vaginalis has numerous proteinases and antibody to trichomonad proteinases. Genitourin Med 1991:67:469-74.
20. Ohlsson K, Bjartell A, Lilja H. Secretory leukocyte protease inhibitor in the male genital tract: PSA-induced proteolytic processing in human semen and tissue localization. J Androl 1995; 16:64-74.
21. Shugars DC, Sauls DL, Weinberg JB. Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immuno-deficiency virus type 1. Oral Dis 1997;3(suppl l):S70-2.
22. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997;3:1141-9.